Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data in sera from patients with anti-tuberculosis drug-induced liver injury

ABSTRACT: Expression data in sera from patients with anti-tuberculosis drug-induced liver injury

PROVIDER: PRJNA593211 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression data in sera from patients with anti-tuberculosis drug-induced liver injury

Project description:The pathogenesis of liver damage induced by anti-tuberculosis drugs is not fully understood, andcurrently, there is no clinically useful biomarker for early diagnosis and treatment.By comparing the differences in the expression of global gene transcripts in the serum of patients with and without anti-tuberculosis drugs induced liver injury, dysregulation genes not only provides a basis for studying pathogenesis, but also provides important information to find new targets for diagnosis and treatment of disease. We used microarrays to detail the global programme of gene expression in sera underlying anti-tuberculosis drug-induced liver injury and identified distinct classes of transcript during this process.

2021-01-01 | GSE141362 | GEO

Small RNAs in anti-tuberculosis drug-induced liver injury

Project description:The antimicrobials isoniazid and pyrazinamide, used for the treatment of tuberculosis are known to cause drug-induced liver injury in humans. This limits the effectiveness of tuberculosis treatment, resulting in incomplete cure, relapse and the development of antimicrobial resistance. MicroRNAs are known to be good biomarkers of disease, with the microRNA miR-122 being diagnostic for liver injury. In this study zebrafish larvae were exposed to the anti-tuberculosis drugs isoniazid and pyrazinamide at concentrations which demonstrated liver injury by microscopy and histology. The aim of this study is to understand small RNA changes occurring in anti-tuberculosis drug-induced liver injury and to attempt to identify novel microRNA biomarkers of liver injury.

2023-12-25 | GSE146260 | GEO

Small RNAs in anti-tuberculosis drug-induced liver injury

Project description:Small RNAs in anti-tuberculosis drug-induced liver injury

| PRJNA609915 | ENA

Genome-wide methylation analysis in Anti-tuberculosis Drug Induced Liver Injury case and control samples

Project description:Association analysis of DNA methylation in Anti-tuberculosis Drug Induced Liver Injury case and control samples from peripheral blood

2021-12-24 | GSE124415 | GEO

Proteomic-based identification of APCS as candidate protein for diagnosis of patients exhibiting Anti-tubercular drug induced liver injury

Project description:In the present study, the proteomics approach identified potential protein signatures with high discriminative ability in TB patients with and without drug-induced liver injury which might play a crucial role in developing Anti-tubercular drug-induced liver injury.

2021-11-12 | MSV000088373 | MassIVE

Genome-wide methylation analysis in Anti-tuberculosis Drug Induced Liver Injury case and control samples

Project description:Genome-wide methylation analysis in Anti-tuberculosis Drug Induced Liver Injury case and control samples

| PRJNA511986 | ENA

Drug-Induced Liver Injury (DILIN) GWAS

Project description:Drug-Induced Liver Injury (DILIN) GWAS

| PRJNA219213 | ENA

Rifampicin-mouse liver proteomics

Project description:Tuberculosis is one of top causes of death among curable infectious diseases; it is an airborne infectious disease that kills 2 million people worldwide. Anti-tuberculosis drug-induced liver injury is the primary cause of drug-induced liver injury (DILI). Rifampicin is one of the most common anti-tuberculosis therapies and has well-known hepatotoxicity. To understand the mechanism of rifampicin-induced liver injury, we performed a global proteomic analysis of liver proteins by LC-MS/MS in a mouse model after the oral administration of 177 and 442.5 mg/kg rifampicin (LD10 and LD25) for 14 days. Based on the biochemical parameters in the plasma after rifampicin treatment, the hepatotoxic effect of rifampicin in the mouse liver was defined as a mixed liver injury. In the present study, we identified 1,101 proteins and quantified 1,038 proteins. A total of 29 and 40 proteins were up-regulated and 27 and 118 proteins were down-regulated in response to 177 and 442.5 mg/kg rifampicin, respectively.

2017-07-10 | PXD006313 | Pride

NIDDK Drug-Induced Liver Injury Network (DILIN)

Project description:<p>The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has established the Drug-Induced Liver Injury Network (DILIN) to collect and analyze cases of severe liver injury caused by prescription drugs, over-the-counter drugs, and alternative medicines, such as herbal products and supplements.</p>

| phs000663 | dbGaP

Transcriptional Response of Mycobacterium tuberculosis to Arabinomannan-specific Immune Sera

Project description:Transcriptional profiling of Mycobacterium tuberculosis H37Rv exposed to immune sera from C57/BL6 mice immunized with a conjugate of Bacillus anthracis protective antigen and arabinomannan vs. protective antigen alone

2017-03-09 | GSE77711 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data